{"text": "Of 20 patients who transitioned from epoprostenol to treprostinil , 5 ultimately transitioned off prostanoid therapy and 3 died .Longitudinal hemodynamic data were available for 10 patients who underwent transition from epoprostenol to treprostinil .", "label": "", "metadata": {}, "score": "30.75493"}
{"text": "There was no significant statistical difference in hemodynamic data after transition from epoprostenol to treprostinil , although there was a trend toward a higher Rp / Rs after transition .", "label": "", "metadata": {}, "score": "33.33177"}
{"text": "This study did not , however , report hemodynamic changes .16 Several other studies demonstrated short - term significant improvements in hemodynamics for pediatric patients on epoprostenol .", "label": "", "metadata": {}, "score": "35.35324"}
{"text": "Over time , there was improvement in Rp / Rs for patients treated with epoprostenol that was not statistically significant and was not sustained ( Table 2 ) .", "label": "", "metadata": {}, "score": "35.658844"}
{"text": "In this randomized , controlled trial , we evaluated the effects of epoprostenol , the pharmacological form of prostacyclin , on echocardiographic abnormalities , cardiac biomarkers and on hemodynamic and respiratory symptoms in patients with pulmonary embolism with echocardiographic signs of right ventricular overload .", "label": "", "metadata": {}, "score": "38.70774"}
{"text": "Based on the improvements in both short - term and long - term outcomes among our patient cohort , epoprostenol is an effective treatment for CTD patients with advanced PAH .", "label": "", "metadata": {}, "score": "38.923046"}
{"text": "In addition , we sought to determine whether treprostinil produces similar hemodynamic changes as epoprostenol de novo or in transition from epoprostenol .Methods .This was a 2-center , retrospective , descriptive study .", "label": "", "metadata": {}, "score": "39.380444"}
{"text": "Because epoprostenol can affect the systemic circulation even more than the pulmonary circulation , these patients would be in danger of severe hypotension and haemodynamic collapse , explain the researchers , which is why they initiated a protocol for use of inotropic agents .", "label": "", "metadata": {}, "score": "40.103134"}
{"text": "Patients not randomised to epoprostenol received a similar syringe pump containing isotonic saline .During titration of epoprostenol infusion , blood pressure , pulse rate and peripheral oxygen saturation were measured at 5 minute intervals .", "label": "", "metadata": {}, "score": "40.491646"}
{"text": "Hemodynamic changes over time on treprostinil were similar to epoprostenol .There was a significant improvement in Rp / Rs on treprostinil after 2 years of therapy and a trend toward improvement on epoprostenol after 1 to 2 years of therapy .", "label": "", "metadata": {}, "score": "40.66254"}
{"text": "As described above , in one patient administraton of epoprostenol could not be increased to a maximum 8 ng / kg / min because of persistent facial flushing and headache .", "label": "", "metadata": {}, "score": "40.762806"}
{"text": "Epoprostenol did not have a significant effect on RVED after 2.5 and 24 hours ( Figure 2 ) .Results were similar for the 3 patients in whom epoprostenol was titrated to a mean dose of 7.2 ng / kg / min ( data not shown ) .", "label": "", "metadata": {}, "score": "41.572803"}
{"text": "\" They stress : \" It is important to initiate epoprostenol therapy before deterioration of the patient 's clinical condition because initiation of epoprostenol therapy is difficult in severely ill patients . \"", "label": "", "metadata": {}, "score": "42.014137"}
{"text": "In addition , obtaining point estimates of effect - size of epoprostenol on primary endpoints may be of use for the design of future studies .", "label": "", "metadata": {}, "score": "43.15966"}
{"text": "In addition , baseline catheterization on epoprostenol occurred at an average of 3.3 years after therapy was initiated , and increased Rp / Rs was seen in patients receiving epoprostenol alone after several years of therapy .", "label": "", "metadata": {}, "score": "43.504433"}
{"text": "These patients were excluded from longitudinal mean Rp / Rs data for epoprostenol and treprostinil in a separate analysis to ensure that the improvements seen were not ascribed to these patients with early death or transplant falling out of the cohort .", "label": "", "metadata": {}, "score": "43.50701"}
{"text": "These limitations notwithstanding , this study demonstrates efficacy of treprostinil equivalent to epoprostenol , with similar long - term outcomes .The largest changes in PVRI and Rp / Rs are seen , in general , within the first 1 to 2 years of therapy .", "label": "", "metadata": {}, "score": "43.679886"}
{"text": "Epoprostenol infusion was continued for 20 hours , then tapered gradually during 4 hours and stopped .Hence , total treatment with epoprostenol or placebo encompassed a period of 24 hours .", "label": "", "metadata": {}, "score": "43.738472"}
{"text": "Between 1992 and 2010 , 79 pediatric patients were treated with epoprostenol or treprostinil for PAH between the 2 institutions .The study excluded 2 patients with left heart obstructive lesions .", "label": "", "metadata": {}, "score": "44.23903"}
{"text": "In considering such a trial , however , one would need to weigh the objective of demonstrating only a potential modest benefit in mortality reduction against the potential safety concerns and the costs of epoprostenol treatment .", "label": "", "metadata": {}, "score": "44.702255"}
{"text": "Selected patients , based on clinician and family preference , are offered treprostinil as an alternative to epoprostenol as initial therapy or to transition from current epoprostenol therapy .", "label": "", "metadata": {}, "score": "45.260986"}
{"text": "It is a short - acting , potent pulmonary and systemic vasodilator with anti - platelet activity .Epoprostenol was first approved for patients with advanced PAH as a continuous intravenous infusion in 1995 .", "label": "", "metadata": {}, "score": "45.318504"}
{"text": "However , hypotension or a decrease in PO 2 ( data not shown ) did not occur in the patients who received epoprostenol infusion in our study .", "label": "", "metadata": {}, "score": "46.041977"}
{"text": "After inclusion of the first 8 subjects , no side effects of epoprostenol treatment at a dose of 4 ng / kg / min were observed .", "label": "", "metadata": {}, "score": "46.33667"}
{"text": "1 , 12 - 15 Treprostinil , via subcutaneous delivery , was initially approved in 2002 for use in patients with PAH to reduce symptoms or to transition from epoprostenol to improve quality of life with its longer half - life .", "label": "", "metadata": {}, "score": "46.714226"}
{"text": "We evaluated the effect of epoprostenol on right ventricular diameter and function in patients with acute pulmonary embolism and right ventricular dilatation .Methods .In a randomized , single - blind study , 14 patients with acute pulmonary embolism received epoprostenol or placebo infusion for 24 hours on top of conventional treatment .", "label": "", "metadata": {}, "score": "47.270065"}
{"text": "In humans with chronic pulmonary hypertension , epoprostenol was associated with unchanged right ventricular dimensions or even increased cardiac output [ 35 , 36 ] .", "label": "", "metadata": {}, "score": "47.615955"}
{"text": "Preparations .Excipients in commercially available drug preparations may have clinically important effects in some individuals ; consult specific product labeling for details .Distribution of iloprost is restricted .", "label": "", "metadata": {}, "score": "47.977898"}
{"text": "Preparations .Excipients in commercially available drug preparations may have clinically important effects in some individuals ; consult specific product labeling for details .Distribution of iloprost is restricted .", "label": "", "metadata": {}, "score": "47.977898"}
{"text": "The improvement in both groups was lost by 3 to 4 years on therapy .Change in pulmonary - to - systemic vascular resistance ratio ( Rp / Rs ) over time on epoprostenol or treprostinil .", "label": "", "metadata": {}, "score": "48.3954"}
{"text": "Patients were randomized to receive intravenous epoprostenol sodium ( Flolan \u00ae ; GSK ; Zeist , the Netherlands ) or saline placebo infusion .Infusion of epoprostenol was started in a dose of 1 ng / kg / min .", "label": "", "metadata": {}, "score": "48.40219"}
{"text": "Storage .Oral Inhalation .Inhalation Solution .Actions .Pharmacologic actions ( e.g. , direct vasodilation of pulmonary and systemic arterial vascular beds , inhibition of platelet aggregation ) similar to those of epoprostenol .", "label": "", "metadata": {}, "score": "48.61251"}
{"text": "Storage .Oral Inhalation .Inhalation Solution .Actions .Pharmacologic actions ( e.g. , direct vasodilation of pulmonary and systemic arterial vascular beds , inhibition of platelet aggregation ) similar to those of epoprostenol .", "label": "", "metadata": {}, "score": "48.61251"}
{"text": "[PubMed ] .Barst RJ , Rubin LJ , Long WA , et al .A comparison of continuous intravenous epoprostenol ( prostacyclin ) with conventional therapy for primary pulmonary hypertension .", "label": "", "metadata": {}, "score": "49.36219"}
{"text": "2 , 3 Multiple studies have demonstrated hemodynamic improvements with sildenafil 4 , 5 or bosentan .6 , 7 Iloprost , an inhaled prostacyclin , has been shown to produce early hemodynamic improvement without significant long - term changes , even in those who had initial improvement . 8 Limited pediatric studies have shown improved survival since therapies specifically indicated for PAH have become available , 9 , 10 although it remains unclear whether this is due to earlier diagnosis , improved follow - up , or the actual therapies .", "label": "", "metadata": {}, "score": "49.528038"}
{"text": "METHODS .This was retrospective study of 77 pediatric patients ( 47 idiopathic PAH , 24 congenital heart disease - PAH ) receiving epoprostenol or treprostinil from 1992 to 2010 at 2 centers .", "label": "", "metadata": {}, "score": "49.755753"}
{"text": "The 3 patients who were treated with increasing dose received 8.0 , 8.0 and 5.6 ng / kg / min epoprostenol respectively .The dose in the last patient could not be raised due to facial flushing and headache .", "label": "", "metadata": {}, "score": "50.343594"}
{"text": "The effect of sequential addition of sildenafil to first - line epoprostenol on exercise capacity measured using 6-min walk distance ( 6MWD ) in the PACES clinical trial ( Pulmonary Arterial Hypertension Combination Study of Epoprostenol and Sildenafil ) .", "label": "", "metadata": {}, "score": "50.71436"}
{"text": "It is , however , possible that a pulmonary vasodilator would have a more pronounced effect in patients with more severe right ventricular dysfunction .The choice for intravenous epoprostenol as a vasodilator merits discussion .", "label": "", "metadata": {}, "score": "51.359356"}
{"text": "Furthermore Troponin T and NT - proBNP were measured serially .Results .Compared to placebo , epoprostenol was associated with a relative change from baseline in right ventricular end - diastolic diameter of +2 % after 2.5 hours and -8 % after 24 hours .", "label": "", "metadata": {}, "score": "51.77223"}
{"text": "This small randomized controlled trial investigated the effect of epoprostenol in patients with acute pulmonary embolism and right ventricular dilatation .In contrast to the results of several case reports and studies in animals , treatment with epoprostenol in humans did not improve right ventricular dilatation or any other measured variables of right ventricular overload .", "label": "", "metadata": {}, "score": "52.096195"}
{"text": "However , inhalation of prostacyclin might increase dead space , possibly due to mucosal swelling [ 32 ] and inhalation of nitric oxide is difficult to implement in patients who are not on mechanical ventilation .", "label": "", "metadata": {}, "score": "52.17991"}
{"text": "Longitudinal hemodynamic data are shown for epoprostenol and treprostinil ( Figure 2 ) .Mean Rp / Rs was compared at baseline with Rp / Rs at 1 , 2 , 3 , and 4 years into therapy for epoprostenol and treprostinil .", "label": "", "metadata": {}, "score": "52.189114"}
{"text": "[ PubMed 16537868 ] .Gomberg - Maitland M , Tapson VF , Benza RL et al .Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension .", "label": "", "metadata": {}, "score": "52.370003"}
{"text": "20 % of starting epoprostenol dosage .90 % of starting epoprostenol dosage .5 % of starting epoprostenol dosage .110 % of starting epoprostenol dosage .", "label": "", "metadata": {}, "score": "52.58989"}
{"text": "Importance of advising patients that subsequent management of PAH may require therapy with an alternate IV prostacyclin therapy ( e.g. , epoprostenol ) .Importance of understanding potential risks associated with therapy .", "label": "", "metadata": {}, "score": "53.301167"}
{"text": "We did not further increase epoprostenol infusion rate because higher doses are usually associated with intolerable side - effects [ 37 ] .Finally , it is also important to point out that other pulmonary vasodilators have different pharmacological properties , and our findings thus can not be extrapolated to these alternatives .", "label": "", "metadata": {}, "score": "53.879406"}
{"text": "RESULTS .Mean age at baseline was 7.7 \u00b1 5.2 years , with follow - up of 4.3 \u00b1 3.4 years .Thirty - seven patients were treated with epoprostenol , 20 with treprostinil , and 20 were transitioned from epoprostenol to treprostinil .", "label": "", "metadata": {}, "score": "53.893017"}
{"text": "It might be argued that right ventricular dysfunction was not severe enough to expect a beneficial effect of epoprostenol .Indeed , TAPSE was at the lower limit of normality , suggesting at most mild right ventricular dysfunction .", "label": "", "metadata": {}, "score": "54.014545"}
{"text": "[PubMed ] .Gomberg - Maitland M , Tapson VF , Benza RL , et al .Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension .", "label": "", "metadata": {}, "score": "54.018433"}
{"text": "Thirdly , it is possible that the dose of epoprostenol was not sufficient to decrease PAP .One might argue that uptitrating iv epoprostenol until systemic side effects like arterial hypotension occur , would be more likely to reveal beneficial effects on right ventricular overload and pulmonary pressures .", "label": "", "metadata": {}, "score": "54.110954"}
{"text": "[ IDIS 480255 ] [ PubMed 11897647 ] .Rubenfire M , McLaughlin VV , Allen RP et al .Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension : a controlled trial .", "label": "", "metadata": {}, "score": "54.468"}
{"text": "Recently published data from the large randomised , double - blind , placebo - controlled PACES ( Pulmonary Arterial Hypertension Combination Study of Epoprostenol and Sildenafil ) trial confirm these findings .", "label": "", "metadata": {}, "score": "54.62741"}
{"text": "Demographic and baseline hemodynamic data were compared among the groups ( epoprostenol vs treprostinil vs transition ) .There were no statistically significant differences among the groups at baseline except age between the treprostinil and transition groups ( Table 1 ) .", "label": "", "metadata": {}, "score": "54.765476"}
{"text": "To view content sources and attributions , please refer to our editorial policy .This study is investigating the effect of switching from Flolan \u00ae to Epoprostenol for Injection ( EFI / ACT-385781A ) in pulmonary arterial hypertension patients currently treated with Flolan \u00ae .", "label": "", "metadata": {}, "score": "54.785515"}
{"text": "Similar improvements have been observed with PDE-5 inhibitors in combination with prostanoids .The appropriate timing of combination therapy requires further evaluation but goal - oriented therapy using combinations of oral and inhaled drugs has been shown to provide acceptable long - term results in patients with advanced PAH .", "label": "", "metadata": {}, "score": "54.827724"}
{"text": "Baseline characteristics , short - term and long - term outcomes , predictors of mortality , and safety profiles were evaluated .For survival analysis , 16 controls were selected who matched the underlying CTD , World Health Organization functional class , and use of PAH drugs , except for epoprostenol .", "label": "", "metadata": {}, "score": "54.92445"}
{"text": "Baseline Characteristics of Patients who Later Transitioned off Epoprostenol or Treprostinil Compared With the Rest of the Cohort .Discussion .Before the availability of specific drugs for PAH , median survival in adults with IPAH was 2.8 years , with a 5-year survival of 34 % .", "label": "", "metadata": {}, "score": "55.051483"}
{"text": "Do not admix iloprost with other orally inhaled drugs .1 Do not use nebulizer to administer any other drugs .Prodose AAD System .Use the manufacturer - supplied pipette to transfer the entire contents of one 20-mcg single - use ampul to the nebulizer drug chamber immediately prior to each inhalation session .", "label": "", "metadata": {}, "score": "55.2752"}
{"text": "Importance of not mixing iloprost with other drugs and of not administering other drugs via the Prodose AAD or I - neb AAD system .Importance of having immediate access to a back - up Prodose AAD or I - neb AAD system in order to avoid potential interruptions in drug therapy secondary to equipment malfunction .", "label": "", "metadata": {}, "score": "55.32154"}
{"text": "Importance of not mixing iloprost with other drugs and of not administering other drugs via the Prodose AAD or I - neb AAD system .Importance of having immediate access to a back - up Prodose AAD or I - neb AAD system in order to avoid potential interruptions in drug therapy secondary to equipment malfunction .", "label": "", "metadata": {}, "score": "55.32154"}
{"text": "In all , 62 patients survived and were discharged to receive home epoprostenol infusion , eight died and one underwent lung transplantation .Patients who died had an increased likelihood of receiving maximal doses of dobutamine and dopamine , relative to those who died .", "label": "", "metadata": {}, "score": "55.340576"}
{"text": "Clearly , the sample size is too small to detect relatively small effects of epoprostenol .However , it should be emphasized that the point estimate of any treatment effect of epoprostenol on right ventricular diameter and function is very small : after 2.5 hours 2 % in favour of placebo , after 24 hours 8 % in favour of epoprostenol .", "label": "", "metadata": {}, "score": "55.355026"}
{"text": "[ PubMed 17261956 ] .Ivy DD , Claussen L , Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil .", "label": "", "metadata": {}, "score": "55.47499"}
{"text": "In humans , a case report suggested that inhaled prostacyclin may also be beneficial for acute pulmonary hypertension associated with pulmonary embolism [ 17 ] .", "label": "", "metadata": {}, "score": "55.806633"}
{"text": "Change in Cardiac Output [ Time Frame : 15 minutes ] [ Designated as safety issue : No ] .On Day 1 patients underwent acute hemodynamic testing prior to and immediately after ( no more than 15 minutes ) the first dose of inhaled iloprost or placebo .", "label": "", "metadata": {}, "score": "56.407436"}
{"text": "On Day 1 patients underwent acute hemodynamic testing prior to and immediately after ( no more than 15 minutes ) the first dose of inhaled iloprost or placebo .", "label": "", "metadata": {}, "score": "56.446342"}
{"text": "Data for NT - proBNP and Troponin T were log - transformed for statistical testing .Adverse events .There were no serious adverse events in either treatment arm .", "label": "", "metadata": {}, "score": "56.759018"}
{"text": "Petkov V , Ziesche R , Mosgoeller W , et al .Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment .", "label": "", "metadata": {}, "score": "56.87365"}
{"text": "Stiebellehner L , Petkov V , Vonbank K , et al .Long - term treatment with oral sildenafil in addition to continuous i.v .epoprostenol in patients with pulmonary arterial hypertension .", "label": "", "metadata": {}, "score": "57.084267"}
{"text": "[ PubMed 17045906 ] .Sitbon O , Manes A , Jais X et al .Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension .", "label": "", "metadata": {}, "score": "57.28463"}
{"text": "Sub - Q or IV .Perform transition in a hospital setting where patient can be closely monitored .Initiate treprostinil at a dosage equivalent to 10 % of the current epoprostenol dosage ; gradually increase treprostinil dosage while simultaneously decreasing dosage of epoprostenol . 1 Manufacturer recommends the following titration protocol : 1 . 40 % of starting epoprostenol dosage .", "label": "", "metadata": {}, "score": "57.312485"}
{"text": "By the time of right heart catheter removal , haemodynamic parameters did not differ between patients who did and did not receive inotropic agents , with the exception of heart rate , which was significantly increased in the dobutamine group .", "label": "", "metadata": {}, "score": "57.353214"}
{"text": "View Article PubMed .Rex S , Missant C , Segers P , Rossaint R , Wouters PF : Epoprostenol treatment of acute pulmonary hypertension is associated with a paradoxical decrease in right ventricular contractilty .", "label": "", "metadata": {}, "score": "57.629646"}
{"text": "In a subgroup analysis , an improvement in exercise capacity was observed in patients who received tadalafil in addition to background bosentan therapy .PDE-5 inhibitors plus prostanoids .", "label": "", "metadata": {}, "score": "57.676624"}
{"text": "Results showed that , compared with placebo , treatment with bosentan produced significant haemodynamic improvements ( reductions in PVR ) and prevented clinical deterioration , including in the subgroup of sildenafil - treated patients .", "label": "", "metadata": {}, "score": "57.98111"}
{"text": "Simonneau G , Rubin LJ , Gali\u00e8 N , et al .Addition of sildenafil to long - term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension : a randomized trial .", "label": "", "metadata": {}, "score": "58.16203"}
{"text": "Drug therapy for PAH , which presently includes prostanoids , ERAs and PDE-5 inhibitors , is recommended in treatment guidelines for most patients with PAH [ 12 - 14 ] .", "label": "", "metadata": {}, "score": "58.997543"}
{"text": "Change in Pulmonary Vascular Resistance [ Time Frame : 15 minutes ] [ Designated as safety issue : No ] .On Day 1 patients underwent acute hemodynamic testing prior to and immediately after ( no more than 15 minutes ) the first dose of inhaled iloprost or placebo .", "label": "", "metadata": {}, "score": "59.065346"}
{"text": "9 The survival reported in this study is similar to or slightly better than previous pediatric and adult studies , suggesting that treprostinil treatment results in similar long - term outcomes to epoprostenol and that both are associated with a survival benefit compared with no therapy .", "label": "", "metadata": {}, "score": "59.3096"}
{"text": "Importance of advising patients to use iloprost only as prescribed with the Prodose AAD system or the I - neb AAD system , in accordance with the manufacturer 's instructions .", "label": "", "metadata": {}, "score": "59.398426"}
{"text": "Importance of advising patients to use iloprost only as prescribed with the Prodose AAD system or the I - neb AAD system , in accordance with the manufacturer 's instructions .", "label": "", "metadata": {}, "score": "59.398426"}
{"text": "Remodulin .Introduction .Uses for Remodulin .Pulmonary Arterial Hypertension .Used parenterally ( as a continuous sub - Q or IV infusion ) for treatment of pulmonary arterial hypertension ( PAH ) in patients with NYHA class II - IV symptoms to reduce symptoms associated with exercise . 1 2 3 Also used parenterally to reduce rate of clinical deterioration in PAH patients who require conversion from epoprostenol therapy ; carefully consider risks and benefits of each drug prior to transition .", "label": "", "metadata": {}, "score": "59.9584"}
{"text": "After each inhalation session , discard any remaining drug solution and clean the nebulizer .1 2 Review manufacturer 's information to ensure proper methods for cleaning , operation , and maintenance of the nebulizer .", "label": "", "metadata": {}, "score": "60.049606"}
{"text": "After each inhalation session , discard any remaining drug solution and clean the nebulizer .1 2 Review manufacturer 's information to ensure proper methods for cleaning , operation , and maintenance of the nebulizer .", "label": "", "metadata": {}, "score": "60.049606"}
{"text": "After each inhalation session , discard any remaining drug solution and clean the nebulizer .1 2 Review manufacturer 's information to ensure proper methods for cleaning , operation , and maintenance of the nebulizer .", "label": "", "metadata": {}, "score": "60.049606"}
{"text": "After each inhalation session , discard any remaining drug solution and clean the nebulizer .1 2 Review manufacturer 's information to ensure proper methods for cleaning , operation , and maintenance of the nebulizer .", "label": "", "metadata": {}, "score": "60.049606"}
{"text": "Change in Diastolic Pulmonary Arterial Pressure [ Time Frame : 15 minutes ] [ Designated as safety issue : No ] .On Day 1 patients underwent acute hemodynamic testing prior to and immediately after ( no more than 15 minutes ) the first dose of inhaled iloprost or placebo .", "label": "", "metadata": {}, "score": "60.063175"}
{"text": "Use caution in patients with moderate or severe ( Child - Pugh class B or C ) hepatic impairment .Elimination of iloprost is reduced and/or systemic exposure is increased after oral or IV administration in patients with impaired hepatic function .", "label": "", "metadata": {}, "score": "60.218605"}
{"text": "Use caution in patients with moderate or severe ( Child - Pugh class B or C ) hepatic impairment .Elimination of iloprost is reduced and/or systemic exposure is increased after oral or IV administration in patients with impaired hepatic function .", "label": "", "metadata": {}, "score": "60.218605"}
{"text": "Hypotensive Effects .Risk of symptomatic hypotension in patients with low systemic arterial pressure receiving orally inhaled treprostinil .Specific Populations .Pregnancy .Lactation .", "label": "", "metadata": {}, "score": "60.44541"}
{"text": "Conclusion .In patients with acute pulmonary embolism and right ventricular overload , treatment with epoprostenol did not improve right ventricular dilatation or any other measured variables of right ventricular overload .", "label": "", "metadata": {}, "score": "60.494537"}
{"text": "Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan .Am J Cardiol 2004 ; 93 : 943 -946 .", "label": "", "metadata": {}, "score": "60.548256"}
{"text": "Previous reports in small populations have shown that pediatric patients with idiopathic PAH ( IPAH ) or PAH associated with congenital heart disease ( CHD ) have experienced clinical improvement 16 and hemodynamic improvement 17 - 19 with epoprostenol therapy .", "label": "", "metadata": {}, "score": "60.62171"}
{"text": "Interactions for Remodulin .Extensively metabolized in liver , principally by CYP2C8 . 1 29 Does not inhibit CYP1A2 , 2A6 , 2C8 , 2C9 , 2C19 , 2D6 , 2E1 , or 3A in vitro . 1 15 Does not induce CYP1A2 , 2B6 , 2C9 , 2C19 , or 3A in vitro . 1 15 Pharmacokinetic interactions with drugs metabolized by the CYP enzyme system are considered unlikely .", "label": "", "metadata": {}, "score": "60.637302"}
{"text": "Currently ( within 30 days prior to RHC ) taking specific pulmonary arterial hypertension ( PAH ) therapy ( e.g. , bosentan , ambrisentan , tadalafil , sildenafil , epoprostenol , treprostinil , iloprost , beraprost ) .", "label": "", "metadata": {}, "score": "60.710045"}
{"text": "References .Simonneau G , Barst RJ , Galie N et al .Continuous subcutaneous infusion of treprostinil , a prostacyclin analogue , in patients with pulmonary arterial hypertension : a double - blind , randomized , placebo - controlled trial .", "label": "", "metadata": {}, "score": "60.77514"}
{"text": "Change in Mean Pulmonary Arterial Pressure [ Time Frame : 15 minutes ] [ Designated as safety issue : No ] .On Day 1 patients underwent acute hemodynamic testing prior to and immediately after ( no more than 15 minutes ) the first dose of inhaled iloprost or placebo .", "label": "", "metadata": {}, "score": "61.103188"}
{"text": "15 16 17 Controlled clinical experience with orally inhaled treprostinil is based primarily on short - term trials in patients receiving the drug as add - on therapy to bosentan or sildenafil .", "label": "", "metadata": {}, "score": "61.24621"}
{"text": "The main objective is to investigate the effect of iloprost on exercise endurance time during constant work rate cardiopulmonary exercise testing .Other efficacy and safety endpoints will additionally be analyzed .", "label": "", "metadata": {}, "score": "61.55254"}
{"text": "Patients who are currently treated with concomitant PAH therapy listed below must have been treated for at least 90 days and on a stable dose for 30 days prior to enrollment : Bosentan , Ambrisentan , Sitaxsentan , Sildenafil , Tadalafil .", "label": "", "metadata": {}, "score": "61.693855"}
{"text": "Median dose ( range ) of epoprostenol was 31 ( 2 - 98 ) , 34 ( 6 - 86 ) , 34 ( 10 - 91 ) , and 34 ( 23 - 77 ) ng / kg / min at 1 , 2 , 3 , and 4 years into therapy respectively .", "label": "", "metadata": {}, "score": "61.80785"}
{"text": "Data from large , adequately powered , randomised controlled trials of combination therapy in PAH are now emerging and suggest that combination therapy may be clinically beneficial .", "label": "", "metadata": {}, "score": "61.871716"}
{"text": "View Article PubMed .Roeleveld RJ , Vonk - Noordegraaf A , Marcus JT , Bronzwaer JG , Marques KM , Postmus PE , Boonstra A : Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension .", "label": "", "metadata": {}, "score": "61.90338"}
{"text": "Renal Impairment .Systemic exposure is increased after IV administration in patients with severe renal impairment requiring intermittent dialysis .1 11 Orally inhaled iloprost has not been evaluated in patients with renal impairment , including those undergoing dialysis .", "label": "", "metadata": {}, "score": "62.29875"}
{"text": "Renal Impairment .Systemic exposure is increased after IV administration in patients with severe renal impairment requiring intermittent dialysis .1 11 Orally inhaled iloprost has not been evaluated in patients with renal impairment , including those undergoing dialysis .", "label": "", "metadata": {}, "score": "62.29875"}
{"text": "Baseline Characteristics of Censored Patients Compared With the Remainder of the Cohort .Thirty - nine patients are still receiving prostanoid therapy , 17 have transitioned to other therapy ( phosphodiesterase inhibitors , endothelin receptor antagonists or inhaled prostacyclins ) , 16 died , and 5 received a heart - lung transplant .", "label": "", "metadata": {}, "score": "62.42257"}
{"text": "9 21 22 25 Limited data indicate that patients whose therapy is transitioned from epoprostenol to IV treprostinil appear to require higher average dosages of treprostinil to maintain the same clinical benefits .", "label": "", "metadata": {}, "score": "63.091515"}
{"text": "Study Evaluations .At baseline , after 2.5 , 24 and 72 hours echocardiographic parameters were obtained .At baseline , after 4 , 24 and 72 hours serum creatine kinase , cardiac troponin T and NT - proBNP were measured .", "label": "", "metadata": {}, "score": "63.37119"}
{"text": "[PubMed ] .McLaughlin VV , Genthner DE , Panella MM , Rich S. Reduction in pulmonary vascular resistance with long - term epoprostenol ( prostacyclin ) therapy in primary pulmonary hypertension .", "label": "", "metadata": {}, "score": "63.482727"}
{"text": "Data from large , adequately powered , randomised controlled trials of combination therapy in PAH are only now being published , with further combination treatment studies still in the pipeline .", "label": "", "metadata": {}, "score": "63.55615"}
{"text": "View Article .Webb SAR , Stott S , Heerden PV : The use of inhaled aerosolized prostacyclin in the treatment of pulmonary hypertension secondary to pulmonary embolism .", "label": "", "metadata": {}, "score": "63.711197"}
{"text": "Treprostinil - based therapy in the treatment of moderate - to - severe pulmonary arterial hypertension : long - term efficacy and combination with bosentan .", "label": "", "metadata": {}, "score": "63.937183"}
{"text": "Similar to the adult data , there were transition failures , 21 which may have resulted from inadequate dose titration or to disease progression .However , successful transition of carefully selected pediatric patients with favorable hemodynamics to oral or inhaled therapies has been reported .", "label": "", "metadata": {}, "score": "63.951607"}
{"text": "20 - 22 The only study on treprostinil use in pediatric patients recently reported hemodynamic improvements in a small cohort .There are no widely accepted standards for initiation of prostanoid therapy in adult or pediatric patients .", "label": "", "metadata": {}, "score": "64.090775"}
{"text": "Outcomes tracked included transition off therapy , heartlung transplantation , and death .At both institutions , epoprostenol therapy is initiated in the cardiac catheterization laboratory or intensive care unit , and the dose is increased to 4 ng / kg / min .", "label": "", "metadata": {}, "score": "64.26495"}
{"text": "During these 90 days safety and tolerability of EFI / ACT-385781A will closely be monitored in all treated patients .This 90 follow - up will provide clinical evidence on the safety , tolerability , efficacy and treatment satisfaction of switching from Flolan \u00ae to EFI / ACT-385781A in patients with pulmonary arterial hypertension .", "label": "", "metadata": {}, "score": "64.3101"}
{"text": "Current use of IV inotropic agents .Current use of any prostacyclin or prostacyclin analog other than Flolan \u00ae .PAH related to any condition other than those specified in the inclusion criteria .", "label": "", "metadata": {}, "score": "64.337006"}
{"text": "There is experimental evidence suggesting that antagonising pulmonary vasoconstriction by administration of selective vasodilators is beneficial .In animal models of acute pulmonary embolism prostacyclin , a relatively selective pulmonary vasodilator , prevented or partially reversed the rise in pulmonary vascular resistance and pressure [ 14 , 15 ] .", "label": "", "metadata": {}, "score": "64.36159"}
{"text": "Significant improvements in exercise capacity from inhaled treprostinil as add - on therapy to bosentan ( or sildenafil ) have since been confirmed in the large , randomised , double - blind , placebo - controlled TRIUMPH I ( Treprostinil Inhalation Used for the Management of Pulmonary Hypertension ) study [ 18 ] .", "label": "", "metadata": {}, "score": "64.75422"}
{"text": "[ PubMed 16151039 ] .McLaughlin VV , Benza RL , Rubin LJ et al .Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension : a randomized controlled clinical trial .", "label": "", "metadata": {}, "score": "64.90181"}
{"text": "Avoid abrupt withdrawal or sudden , large dosage reductions ; may result in worsening of PAH symptoms .Hematologic Effects .Possible increased risk of bleeding , particularly in patients receiving anticoagulant therapy .", "label": "", "metadata": {}, "score": "64.90776"}
{"text": "Kaplan - Meier survival curve for the entire cohort , comprising patients on epoprostenol , treprostinil , and those who transitioned , with 95 % confidence intervals ( CI ) depicted .", "label": "", "metadata": {}, "score": "65.11684"}
{"text": "May use either the 10-mcg ( 1-mL ) ampul or the 20-mcg ( 2-mL ) ampul of iloprost .", "label": "", "metadata": {}, "score": "65.19524"}
{"text": "May use either the 10-mcg ( 1-mL ) ampul or the 20-mcg ( 2-mL ) ampul of iloprost .", "label": "", "metadata": {}, "score": "65.19524"}
{"text": "The appropriate design to assess the efficacy of this strategy appears to be a three - arm study , comparing combination therapy with two arms of monotherapy using the single compounds .", "label": "", "metadata": {}, "score": "65.40954"}
{"text": "Change in Right Ventricular Pressure [ Time Frame : 15 minutes ] [ Designated as safety issue : No ] .On Day 1 patients underwent acute hemodynamic testing prior to and immediately after ( no more than 15 minutes ) the first dose of inhaled iloprost or placebo .", "label": "", "metadata": {}, "score": "65.61865"}
{"text": "1 Do not use nebulizer to administer any other drugs .Prodose AAD System .Use the manufacturer - supplied pipette to transfer the entire contents of one 20-mcg single - use ampul to the nebulizer drug chamber immediately prior to each inhalation session .", "label": "", "metadata": {}, "score": "65.673454"}
{"text": "View Article PubMed .Tanus - Santos JE , Gordo WM , Udelsmann A , Cittadino MH , Moreno H : Nonselective endothelin - receptor antagonism attenuates hemodynamic changes after massive pulmonary air embolism in dogs .", "label": "", "metadata": {}, "score": "65.696"}
{"text": "Combination therapy proved both efficacious and well tolerated ; syncope was notably less frequent and severe in the combination treatment arm than that reported in the AIR ( Aerosolised Iloprost Randomised ) study , possibly because of background bosentan therapy .", "label": "", "metadata": {}, "score": "65.7834"}
{"text": "PMID : 23359006 Owner : NLM Status : Publisher .Abstract / OtherAbstract : .OBJECTIVE :To assess the efficacy of epoprostenol treatment in Japanese patients with pulmonary arterial hypertension ( PAH ) associated with connective tissue disease ( CTD ) .", "label": "", "metadata": {}, "score": "65.86621"}
{"text": "Importance of having immediate access to a back - up pump and infusion sets ( when administered parenterally ) or a back - up Optineb - ir device ( when administered via oral inhalation ) in order to avoid potential interruptions in drug therapy secondary to drug delivery device failure or equipment malfunction .", "label": "", "metadata": {}, "score": "65.92345"}
{"text": "[ Time Frame : Approximately 3 months ] [ Designated as safety issue : No ] .Patients were required to complete the TSQM-9 questionnaire at Screening or Day 1 , prior to switch from Flolan \u00ae to EFI / ACT-385781A and at EOT .", "label": "", "metadata": {}, "score": "66.003494"}
{"text": "[ Time Frame : Approximately 3 months ] [ Designated as safety issue : No ] .Patients were required to complete the TSQM-9 questionnaire at Screening or Day 1 , prior to switch from Flolan \u00ae to EFI / ACT-385781A and at EOT .", "label": "", "metadata": {}, "score": "66.003494"}
{"text": "[ Time Frame : Approximately 3 months ] [ Designated as safety issue : No ] .Patients were required to complete the TSQM-9 questionnaire at Screening or Day 1 , prior to switch from Flolan \u00ae to EFI / ACT-385781A and at EOT .", "label": "", "metadata": {}, "score": "66.003494"}
{"text": "[ PubMed 20133511 ] .Laliberte K , Arneson C , Jeffs R et al .Pharmacokinetics and steady - state bioequivalence of treprostinil sodium ( Remodulin ) administered by the intravenous and subcutaneous route to normal volunteers .", "label": "", "metadata": {}, "score": "66.56926"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01431716 .Abstract .BACKGROUND .Pediatric patients with severe pulmonary arterial hypertension ( PAH ) are treated with intravenous epoprostenol or intravenous or subcutaneous treprostinil .", "label": "", "metadata": {}, "score": "66.66234"}
{"text": "Now , however , as data from clinical trials designed to evaluate the efficacy and safety of combination therapy has become available , this approach may be revised .", "label": "", "metadata": {}, "score": "66.72075"}
{"text": "Iloprost .Administration .Oral Inhalation .Administer using the Prodose AAD system jet nebulizer or the I - neb AAD system ultrasonic nebulizer .1 2 3 6 14 Safety and efficacy of administering iloprost via nebulizers other than the Prodose AAD or I - neb AAD system have not been established .", "label": "", "metadata": {}, "score": "66.73601"}
{"text": "View Article PubMed .Bottiger BW , Motsch J , Dorsam J , Mieck U , Gries A , Weimann J , Martin E : Inhaled nitric oxide selectively decreases pulmonary artery pressure and pulmonary vascular resistance following acute massive pulmonary microembolism in piglets .", "label": "", "metadata": {}, "score": "66.883835"}
{"text": "The chronic and rapidly progressive nature of PAH provides a strong rationale for use of combination therapy ; indeed , combination therapy is now recommended in new treatment guidelines .", "label": "", "metadata": {}, "score": "67.006424"}
{"text": "Other Pulmonary Disorders .Specific Populations .Pregnancy .Lactation .Not known whether iloprost is distributed into milk .1 Discontinue nursing or the drug .", "label": "", "metadata": {}, "score": "67.311554"}
{"text": "Other Pulmonary Disorders .Specific Populations .Pregnancy .Lactation .Not known whether iloprost is distributed into milk .1 Discontinue nursing or the drug .", "label": "", "metadata": {}, "score": "67.311554"}
{"text": "Thus , there is still a need for further treatment options in those patients who do not stabilise on monotherapy and for those who show initial symptomatic improvements but later regress [ 7 ] .", "label": "", "metadata": {}, "score": "67.41598"}
{"text": "PubMed ] .Sitbon O , Humbert M , Nunes H , et al .Long - term intravenous epoprostenol infusion in primary pulmonary hypertension : prognostic factors and survival .", "label": "", "metadata": {}, "score": "67.4356"}
{"text": "Elimination Route .Following oral and IV administration , 81 % of radiolabeled dose is recovered in urine ( 68 % ) and feces ( 12 % ) within 14 hours .", "label": "", "metadata": {}, "score": "67.46642"}
{"text": "Elimination Route .Following oral and IV administration , 81 % of radiolabeled dose is recovered in urine ( 68 % ) and feces ( 12 % ) within 14 hours .", "label": "", "metadata": {}, "score": "67.46642"}
{"text": "Change in Mean Right Atrial Pressure [ Time Frame : 15 minutes ] [ Designated as safety issue : No ] .On Day 1 patients underwent acute hemodynamic testing prior to and immediately after ( no more than 15 minutes ) the first dose of inhaled iloprost or placebo .", "label": "", "metadata": {}, "score": "67.49098"}
{"text": "View Article .Kerbaul F , Brimioulle S , Rondelet B , Dewachter C , Hubloue I , Naeije R : How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension .", "label": "", "metadata": {}, "score": "67.61801"}
{"text": "We postulate that the lack of long - term improvement may be due to progression of underlying disease .Alternatively , there could be tolerance to prostanoid therapy with inadequate dose titration over time , although this has not been substantiated .", "label": "", "metadata": {}, "score": "67.70594"}
{"text": "Gruenig E , Michelakis E , Vachiery J - L , et al .Acute hemodynamic effects of single - dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension : results of the COMPASS-1 study .", "label": "", "metadata": {}, "score": "67.798355"}
{"text": "Excipients in commercially available drug preparations may have clinically important effects in some individuals ; consult specific product labeling for details .Treprostinil Sodium .Parenteral .", "label": "", "metadata": {}, "score": "67.83591"}
{"text": "In this review , we will discuss the rationale for using combination therapy in PAH , examine the growing body of evidence to support its clinical use , and consider which patients might benefit most .", "label": "", "metadata": {}, "score": "67.94854"}
{"text": "Moreover , with evidence to suggest that at least three separate pathways are involved in the pathogenesis of PAH , there is a sound rationale for the concomitant use of two or more drugs in the treatment of PAH .", "label": "", "metadata": {}, "score": "68.04338"}
{"text": "This may also be the explanation for the minimal effect of the serotonin receptor blocker ketanserin on PAP and cardiac output in patients with acute pulmonary embolism [ 28 ] .", "label": "", "metadata": {}, "score": "68.10359"}
{"text": "The BREATHE-2 trial ( Bosentan Randomised Trial of Endothelin Antagonist Therapy for PAH ) was the first randomised , double - blind , placebo - controlled study to explore the potential clinical benefits of simultaneously combining bosentan with epoprostenol in treatment of severe PAH ( WHO functional class III / IV ) [ 15 ] .", "label": "", "metadata": {}, "score": "68.15797"}
{"text": "Patients receiving prostanoid therapy undergo repeat catheterization yearly or sooner if there are significant clinical concerns .Baseline catheterization in this study was defined as catheterization before initiation of prostanoid therapy .", "label": "", "metadata": {}, "score": "68.189285"}
{"text": "Ruiz MJ , Escribano P , Delgado JF , et al .Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long - term treatment with prostanoids : 2-year experience .", "label": "", "metadata": {}, "score": "68.21781"}
{"text": "View Article .Montalescot G , Drobinski G , Meurin P , Maclouf J , Sotirov I , Philippe F , Choussat R , Morin E , Thomas D : Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end - stage heart failure .", "label": "", "metadata": {}, "score": "68.41286"}
{"text": "[ PubMed 20430262 ] .Channick RN , Olschewski H , Seeger W et al .Safety and efficacy of inhaled treprostinil as add - on therapy to bosentan in pulmonary arterial hypertension .", "label": "", "metadata": {}, "score": "68.47932"}
{"text": "Known hypersensitivity to iloprost or any of the excipients of the drug formulations .Choosing to participate in a study is an important personal decision .", "label": "", "metadata": {}, "score": "68.5204"}
{"text": "Absorption .Bioavailability .Distribution .Extent .Plasma Protein Binding .Elimination .Metabolism .Undergoes \u03b2 - oxidation of the carboxyl side chain .", "label": "", "metadata": {}, "score": "68.61602"}
{"text": "Absorption .Bioavailability .Distribution .Extent .Plasma Protein Binding .Elimination .Metabolism .Undergoes \u03b2 - oxidation of the carboxyl side chain .", "label": "", "metadata": {}, "score": "68.61602"}
{"text": "View Article PubMed .Webb SAR , Stott S , Heerden PV : The use of inhaled aerosolized prostacyclin in the treatment of pulmonary hypertension secondary to pulmonary embolism .", "label": "", "metadata": {}, "score": "68.70259"}
{"text": "WHEN SHOULD COMBINATION THERAPY BE CONSIDERED ?At present there is no known cure for PAH , thus current therapy aims to improve and/or stabilise haemodynamics , symptoms such as dyspnoea , exercise capacity , HRQoL , morbidity ( including hospitalisation ) and survival [ 12 ] .", "label": "", "metadata": {}, "score": "68.96664"}
{"text": "[ PubMed 17332729 ] .Gotzkowsky SK , Dingemanse J , Lai A et al .Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers .", "label": "", "metadata": {}, "score": "69.10626"}
{"text": "Importance of advising patient that treprostinil is infused continuously through a self - inserted sub - Q or surgically placed indwelling central venous catheter , via an infusion pump , which will require a long - term commitment on the part of the patient .", "label": "", "metadata": {}, "score": "69.24319"}
{"text": "2007 ; 132 ( suppl ) .Abstract No . 474b .Centers for Disease Control and Prevention ( CDC ) .Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension -- seven sites , United States , 2003 - 2006 .", "label": "", "metadata": {}, "score": "69.24541"}
{"text": "Safety and efficacy of orally inhaled treprostinil not established in patients with lung disease ( i.e. , asthma , COPD ) .15 Monitor patients who develop acute pulmonary infections for any worsening of lung disease and loss of drug effect .", "label": "", "metadata": {}, "score": "69.29544"}
{"text": "[PubMed ] .Lammers AE , Hislop AA , Flynn Y , Haworth SG .Epoprostenol treatment in children with severe pulmonary hypertension .Heart .", "label": "", "metadata": {}, "score": "69.410446"}
{"text": "[ PubMed 17010807 ] .Voswinckel R , Enke B , Reichenberger F et al .Favorable effects of inhaled treprostinil in severe pulmonary hypertension : results from randomized controlled pilot studies .", "label": "", "metadata": {}, "score": "69.64491"}
{"text": "Pediatric Use . 1 Titrate dosage carefully .Geriatric Use .Hepatic Impairment .Adjust dosage of sub - Q or IV treprostinil in patients with mild to moderate hepatic impairment . 1 ( See Hepatic Impairment under Dosage and Administration . )", "label": "", "metadata": {}, "score": "69.6741"}
{"text": "Common Adverse Effects .Interactions for Iloprost .Minimally metabolized by CYP isoenzymes . 1 Does not inhibit CYP enzyme system . 1 Pharmacokinetic interaction unlikely with drugs metabolized by CYP isoenzymes .", "label": "", "metadata": {}, "score": "69.72049"}
{"text": "Individually titrate treprostinil dosage to allow transition from epoprostenol therapy while balancing symptoms of PAH and prostacyclin - related adverse effects . 1 Manage any increase in PAH symptoms ( e.g. , shortness of breath ) by initially increasing dosage of treprostinil ; manage symptoms of excess prostacyclin ( e.g. , facial flushing , headache , jaw pain ) by initially decreasing dosage of epoprostenol .", "label": "", "metadata": {}, "score": "69.77229"}
{"text": "Recently , Van Loon et al 10 reported 5-year survival of 66 % in pediatric patients with IPAH or CHD - PAH when current era drugs became available during the disease course without improvement in survival when the drugs were available at diagnosis .", "label": "", "metadata": {}, "score": "69.79881"}
{"text": "Despite one clinical trial showing some benefit of thrombolysis in normotensive patients with pulmonary embolism and echocardiographic signs of right ventricular dysfunction [ 5 ] , thrombolytic therapy continues to be highly controversial in this patient category [ 6 - 8 ] .", "label": "", "metadata": {}, "score": "69.92238"}
{"text": "Patients should have immediate access to a back - up system in the event of equipment malfunction .Patients should be trained in proper administration ( including dosing frequency ) , manipulation of glass iloprost ampuls , and nebulizer operation / maintenance .", "label": "", "metadata": {}, "score": "69.99895"}
{"text": "Change in Pulmonary - to - Systemic Vascular Resis tance Ratio Over Time in Patients Receiving Epoprostenol or Treprostinil a .Similar changes occurred in PVR index ( PVRI ) and mean pulmonary artery pressure ( mPAP ; Figure 3 . )", "label": "", "metadata": {}, "score": "70.2762"}
{"text": "Modest and temporary effects on QT c interval observed following single oral inhalation doses ; possibly an artifact of the rapidly changing heart rate produced by the drug . 1 15 Effects of parenteral treprostinil on QT c not studied .", "label": "", "metadata": {}, "score": "70.42057"}
{"text": "Consult manufacturer 's labeling for additional information on administration of IV treprostinil .Dilution .Must be diluted with sterile water for injection , 0.9 % sodium chloride injection , or Flolan sterile diluent for injection prior to IV administration .", "label": "", "metadata": {}, "score": "70.558334"}
{"text": "Evian , France : 1998 Sep 6 - 10 .McLaughlin VV , Oudiz R , Frost A et al .A randomized double - blind , placebo - controlled study of iloprost inahalation as add - on therapy to bosentan in pulmonary arterial hypertension ( PAH ) .", "label": "", "metadata": {}, "score": "70.6306"}
{"text": "Evian , France : 1998 Sep 6 - 10 .McLaughlin VV , Oudiz R , Frost A et al .A randomized double - blind , placebo - controlled study of iloprost inahalation as add - on therapy to bosentan in pulmonary arterial hypertension ( PAH ) .", "label": "", "metadata": {}, "score": "70.6306"}
{"text": "McLaughlin VV , Gaine SP , Barst RJ , et al .Efficacy and safety of treprostinil : an epoprostenol analog for primary pulmonary hypertension .", "label": "", "metadata": {}, "score": "70.66267"}
{"text": "This study examined predictors of survival in pediatric patients with PAH on prostanoid therapy .Adult studies demonstrated decreased survival , with elevated RAP , mPAP , PVRI and decreased CI . 1 , 3 - 15 Similarly , elevated Rp / Rs , RAP , and PVRI ( but not CI ) were significantly associated with early death or transplant in this cohort .", "label": "", "metadata": {}, "score": "70.9072"}
{"text": "Iloprost .Routes .Dosage Forms .10 mcg / mL ( 10 mcg , 20 mcg ) .Ventavis ( with alcohol ; preservative - free , available with Prodose AAD or I - neb AAD system ) .", "label": "", "metadata": {}, "score": "71.72686"}
{"text": "Iloprost .Routes .Dosage Forms .10 mcg / mL ( 10 mcg , 20 mcg ) .Ventavis ( with alcohol ; preservative - free , available with Prodose AAD or I - neb AAD system ) .", "label": "", "metadata": {}, "score": "71.72686"}
{"text": "Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high - dose epoprostenol .Circ J 2008 ; 72 : 1142 -1146 .", "label": "", "metadata": {}, "score": "71.98073"}
{"text": "View Article PubMed .Dias - Junior CA , Vieira TF , Moreno H , Evora PR , Tanus - Santos JE : Sildenafil selectively inhibits acute pulmonary embolism - induced pulmonary hypertension .", "label": "", "metadata": {}, "score": "72.150665"}
{"text": "Gali\u00e8 N , Rubin LJ , Hoeper M , et al .Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan ( EARLY study ) : a double - blind , randomised controlled trial .", "label": "", "metadata": {}, "score": "72.339584"}
{"text": "Importance of advising patients to avoid skin or eye contact with treprostinil oral inhalation solution .15 If skin or eye contact occurs , instruct patient to immediately rinse the affected area with water .", "label": "", "metadata": {}, "score": "72.412674"}
{"text": "Administration .Administer by continuous sub - Q or IV infusion , or by oral inhalation .When administered parenterally , sub - Q route generally preferred ; reserve IV use for patients who can not tolerate sub - Q therapy ( e.g. , due to infusion - site pain or reaction ) or in whom risks of IV therapy are considered warranted .", "label": "", "metadata": {}, "score": "72.45532"}
{"text": "Pre - publication history .Copyright .\u00a9Kooter et al .2010 .This article is published under license to BioMed Central Ltd.Inotropic agents support epoprostenol initiation in severe PAH .", "label": "", "metadata": {}, "score": "72.78424"}
{"text": "Konstantinides S , Geibel A , Geusel G , Heinrich F , Kasper W : Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism .", "label": "", "metadata": {}, "score": "72.79162"}
{"text": "Consult manufacturer 's labeling for additional information on preparation of IV treprostinil .Oral Inhalation .Treprostinil inhalation solution is for oral inhalation only ; do not ingest .", "label": "", "metadata": {}, "score": "72.84472"}
{"text": "Currently , combination therapy appears best suited to patients with suboptimal response to therapy , such as those in WHO functional class III / IV who fail to improve on initial therapy and those in WHO functional class II who fail to stabilise .", "label": "", "metadata": {}, "score": "73.1091"}
{"text": "The average Rp / Rs before transition off prostanoid therapy was 0.5 \u00b1 0.2 and did not change on follow - up catheterization .Kaplan - Meier 5-year transplant - free survival for the entire cohort was 70 % ( 95 % confidence interval 56%-80 % ; Figure 5 ) .", "label": "", "metadata": {}, "score": "73.25678"}
{"text": "[PubMed ] .Balzer DT , Kort HW , Day RW , et al .Inhaled nitric oxide as a preoperative test ( INOP test I : The INOP Test Study Group .", "label": "", "metadata": {}, "score": "73.500465"}
{"text": "[ PubMed 17400684 ] .Tapson VF , Gomberg - Maitland M , McLaughlin VV et al .Safety and efficacy of IV treprostinil for pulmonary arterial hypertension : a prospective , multicenter , open - label , 12-week trial .", "label": "", "metadata": {}, "score": "73.548645"}
{"text": "Biochemical paramaters improved in both groups .Systolic PAP at baseline and follow up for both treatment groups is presented in Figure 3 .Values are given as the mean \u00b1 SD .", "label": "", "metadata": {}, "score": "73.6015"}
{"text": "Functional class , CI at baseline , and reduction of mPAP at 6 months were identified as predictors of survival .Adverse events , including flushing and catheter - related infection , were frequent , but all patients tolerated the treatment .", "label": "", "metadata": {}, "score": "73.64786"}
{"text": "19 Finally , a recent report in 8 patients demonstrated short - term ( 6 - 18 month ) improvement in CI and PVRI on subcutaneous treprostinil .", "label": "", "metadata": {}, "score": "73.8162"}
{"text": "Discussion .This is the first study to investigate the effect of a vasodilator for treatment of acute pulmonary embolism in a randomized controlled trial .", "label": "", "metadata": {}, "score": "74.18768"}
{"text": "Garc\u00eda Hern\u00e1ndez FJ , Oca\u00f1a Medina C , Mateos Romero L , et al .Combined treatment with intravenous prostacyclin and sildenafil in patients with pulmonary hypertension : report of 4 cases .", "label": "", "metadata": {}, "score": "74.27272"}
{"text": "Initial reports of pediatric survival were far worse than that for adults . 1 With the advent of multiple available therapies ( although none are approved by the U.S. Food and Drug Administration for pediatric patients ) , pediatric survival has improved .", "label": "", "metadata": {}, "score": "74.285446"}
{"text": "Oral inhalation results in alveolar drug deposition and possibly greater selectivity for pulmonary vasculature .Advice to Patients .Importance of providing patient a copy of the manufacturer 's patient information and a copy of the user guide for the Prodose AAD system or the I - neb AAD system .", "label": "", "metadata": {}, "score": "74.339905"}
{"text": "Oral inhalation results in alveolar drug deposition and possibly greater selectivity for pulmonary vasculature .Advice to Patients .Importance of providing patient a copy of the manufacturer 's patient information and a copy of the user guide for the Prodose AAD system or the I - neb AAD system .", "label": "", "metadata": {}, "score": "74.339905"}
{"text": "View Article .Bratel T , Lagerstrand L , Brodin L , Nowak J , Randmaa I : Ventilation - perfusion relationships in pulmonary arterial hypertension : Effect of intravenous and inhaled prostacyclin treatment .", "label": "", "metadata": {}, "score": "74.4848"}
{"text": "Data taken from [ 20 ] .More recently , data were reported from the PHIRST-1 study ( Tadalafil in the Treatment of Pulmonary Arterial Hypertension ) , a randomised , double - blind , placebo - controlled trial in 405 patients with PAH treated with tadalafil [ 21 ] .", "label": "", "metadata": {}, "score": "74.75798"}
{"text": "The absence of a decrease in systolic PAP in either treatment group may indicate that patients were already past the phase of acute pulmonary vasocontriction .", "label": "", "metadata": {}, "score": "74.82379"}
{"text": "To avoid potential interruptions in drug delivery , patient must have immediate access to backup infusion pump and sub - Q infusion sets ( since abrupt withdrawal or sudden , large dosage reductions may result in worsening of PAH symptoms ) .", "label": "", "metadata": {}, "score": "74.90064"}
{"text": "Abstract .There is a strong clinical rationale for combination therapy in pulmonary arterial hypertension ( PAH ) , as several pathological pathways have been implicated in its pathogenesis and no single agent has yet been shown to deliver completely satisfactory results .", "label": "", "metadata": {}, "score": "74.92839"}
{"text": "From Baseline to EOT .[ Time Frame : Approximately 3 months ] [ Designated as safety issue : No ] .NYHA FC was assessed at Screening or Day 1 , prior to switch from Flolan \u00ae to EFI / ACT-385781A and at EOT .", "label": "", "metadata": {}, "score": "75.20958"}
{"text": "Therapy may be continued for prolonged periods ; carefully consider patient 's ability to administer the drug and care for an infusion system ( when drug is given parenterally ) .", "label": "", "metadata": {}, "score": "75.30571"}
{"text": "[PubMed ] .Ivy DD , Doran AK , Smith KJ , et al . Short- and long - term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension .", "label": "", "metadata": {}, "score": "75.32651"}
{"text": "1 Sub - Q route of administration is preferred when the drug is given parenterally .Adequate Patient Evaluation and Monitoring .Use only under the supervision of a qualified clinician experienced in the diagnosis and management of PAH .", "label": "", "metadata": {}, "score": "75.350235"}
{"text": "Primary Purpose : Treatment .Official Title : .A Phase 2 , Multi - center , Double - blind , Randomized , Placebo - controlled Study to Evaluate the Effects of Inhaled Iloprost on Endurance Time During Cardiopulmonary Exercise Testing in Patients With Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease .", "label": "", "metadata": {}, "score": "75.4684"}
{"text": "View Article PubMed .Capellier G , Jacques T , Balvay P , Blasco G , Belle E , Barale F : Inhaled nitric oxide in patients with pulmonary embolism .", "label": "", "metadata": {}, "score": "75.61926"}
{"text": "Prior to first inhalation session , transfer entire contents of a single 2.9-mL ampul of drug into medicine cup supplied by the manufacturer .", "label": "", "metadata": {}, "score": "75.66083"}
{"text": "A single - lumen Broviac catheter is used for infusion with a CADD legacy infusion pump ( Pharmacia Deltec , St. Paul , MN ) for epoprostenol or a CADD Legacy , CADD MS3 , or Crono Five pump ( Cane , Torino , Italy ) for treprostinil .", "label": "", "metadata": {}, "score": "75.77004"}
{"text": "384 , e371 - 2 .[ PMC free article ] [ PubMed ] .Humpl T , Reyes JT , Holtby H , Stephens D , Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension : twelve - month clinical trial of a single - drug , open - label , pilot study .", "label": "", "metadata": {}, "score": "75.841866"}
{"text": "View Article PubMed . O'Grady J , Warrington S , Moti MJ : Effects of intravenous infusion of prostacyclin ( PGI2 ) in man .Prostaglandin 1980 , 19 : 319 - 332 .", "label": "", "metadata": {}, "score": "76.131744"}
{"text": "In animal models of acute pulmonary embolism , treatment with different vasodilators , including prostacyclin , was associated with a more pronounced decrease in mean PAP of 12 - 33 % [ 14 , 25 - 27 ] .", "label": "", "metadata": {}, "score": "76.17435"}
{"text": "15 Patients should have access to a back - up Optineb - ir device in the event of equipment malfunction .15 Instruct patients on proper administration ( including dosing frequency ) , use , and maintenance of Optineb - ir device .", "label": "", "metadata": {}, "score": "76.20323"}
{"text": "PubMed .Ueno Y , Kawashima A , Koike H , Nishio S : Effect of beraprost sodium , a stable prostacyclin analogue , on pulmonary thromboembolism in mice .", "label": "", "metadata": {}, "score": "76.6712"}
{"text": "12 - 15 Sitbon et al 15 reported hemodynamic improvement at 1 year in 156 patients with IPAH on epoprostenol with a 5-year survival of 55 % .", "label": "", "metadata": {}, "score": "76.767166"}
{"text": "Further studies are needed to refine longer - term hemodynamic changes and survival for both prostanoids .Acknowledgments .This study was supported by the Jayden DeLuca Foundation , the Leah Bult Foundation , and UL1 RR025780 Colorado Clinical Translational Science Institute , National Center for Research Resources , and National Institutes of Health .", "label": "", "metadata": {}, "score": "76.924576"}
{"text": "[ PubMed 17317374 ] .Feldman JP , Chakinala M , Torres F et al .Treprostinil sodium improves exercise capacity when added to existing oral pulmonary arterial hypertension therapy .", "label": "", "metadata": {}, "score": "76.93317"}
{"text": "Oral Inhalation .Initially , 18 mcg ( 3 inhalations ) per treatment session 4 times daily .15 If initial dosage not tolerated , reduce to 1 or 2 inhalations per treatment session , then increase up to 3 inhalations as tolerated .", "label": "", "metadata": {}, "score": "77.108116"}
{"text": "Obviously any clinical benefit to be derived from combining two or more drugs has to be considered in light of the risk of drug - drug interactions and the possible increased risk of side - effects .", "label": "", "metadata": {}, "score": "77.82885"}
{"text": "[PubMed ] .McLaughlin VV , Shillington A , Rich S. Survival in primary pulmonary hypertension : the impact of epoprostenol therapy .Circulation .", "label": "", "metadata": {}, "score": "77.951126"}
{"text": "From Baseline to EOT .[ Time Frame : Approximately 3 months ] [ Designated as safety issue : No ] .The 6MWD was assessed at Screening or Day 1 , prior to switch from Flolan \u00ae to EFI / ACT-385781A and at EOT .", "label": "", "metadata": {}, "score": "77.9888"}
{"text": "Intravenous therapy is typically reserved for those patients in whom oral therapy is not successful or those with severe disease , defined as systemic pulmonary arterial pressure with symptoms ( New York Heart Association class III or IV ) , supra - systemic pulmonary arterial pressure , or concerning symptoms .", "label": "", "metadata": {}, "score": "78.21005"}
{"text": "ERA plus PDE-5 inhibitors .Both bosentan and PDE-5 inhibitors are administered orally , making concomitant administration simple and convenient .Evidence that bosentan in combination with sildenafil may benefit patients with mildly symptomatic disease ( WHO functional class II ) emerged from the EARLY ( Endothelin Antagonist Trial in Mildly Symptomatic PAH patients ) trial that included a subgroup of patients treated with sildenafil [ 19 ] .", "label": "", "metadata": {}, "score": "78.22182"}
{"text": "View Article PubMed .Paramothayan NS , Lasserson TJ , Wells AU , Goldhaber SZ : Prostacyclin for pulmonary hypertension in adults .Cochrane Database Syst Rev ( database online ) 2005 . , ( 2 ) : .", "label": "", "metadata": {}, "score": "78.2303"}
{"text": "View Article PubMed .Huet Y , Brun - Buisson C , Lemaire F , Teisseire B , Lhoste F , Rapin M : Cardiopulmonary effects of ketanserin infusion in human pulmonary embolism .", "label": "", "metadata": {}, "score": "78.30355"}
{"text": "J Am Coll Cardiol 1985 , 6 : 750 - 756 .View Article PubMed .Konstantinides S , Geibel A , Olschewski M , Heinrich F , Grosser K , Rauber K , Iversen S , Redecker M , Kienast J , Just H , Kasper W : Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism .", "label": "", "metadata": {}, "score": "78.31726"}
{"text": "15 Discard medicine cup and any unused solution at end of each day and clean Optineb - ir device according to manufacturer 's instructions .Dosage .", "label": "", "metadata": {}, "score": "78.39691"}
{"text": "Controlled clinical trials are underway that will provide important answers to the long - term safety and efficacy of combination therapy in PAH .Statement of interest .", "label": "", "metadata": {}, "score": "78.414116"}
{"text": "View Article PubMed .B\u00fcller HR , Agnelli G , Hull RD , Hyers TM , Prins MH , Raskob GE : Antithrombotic therapy for venous thromboembolic disease : the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy .", "label": "", "metadata": {}, "score": "78.91394"}
{"text": "To view content sources and attributions , please refer to our editorial policy .Ventavis .Administration .Oral Inhalation .Administer using the Prodose AAD system jet nebulizer or the I - neb AAD system ultrasonic nebulizer .", "label": "", "metadata": {}, "score": "79.328964"}
{"text": "PubMed ] .Rosenzweig EB , Ivy DD , Widlitz A , et al .Effects of long - term bosentan in children with pulmonary arterial hypertension .", "label": "", "metadata": {}, "score": "79.361496"}
{"text": "[PubMed ] .Levy M , Celermajer DS , Bourges - Petit E , Del Cerro MJ , Bajolle F , Bonnet D. Add - on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension .", "label": "", "metadata": {}, "score": "79.38154"}
{"text": "Cardiac catheterization data were extracted from existing institutional databases .24 When used , PVR was recalculated from raw hemodynamic data using oxygen consumption from the Bergstra equation to ensure standardization across patients and between institutions .", "label": "", "metadata": {}, "score": "79.575874"}
{"text": "View Article PubMed .Hamel E , Pacouret G , Vincentelli D , Forissier JF , Peijcher P , Pottier JM , Charbonnier B : Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation .", "label": "", "metadata": {}, "score": "79.68765"}
{"text": "Utsonomiya T , Krausz MM , Levine L , Sherpo D , Hechtman HB : Thromboxane mediation of cardiopulmonary effects of embolism .J Clin Invest 1982 , 70 : 361 - 368 .", "label": "", "metadata": {}, "score": "79.823074"}
{"text": "Monitor vital signs , especially BP , closely during initiation of iloprost .Adults .Pulmonary Arterial Hypertension .Oral Inhalation .Administer 6 - 9 times daily at minimum intervals of 2 hours while awake according to clinical response .", "label": "", "metadata": {}, "score": "80.168915"}
{"text": "Monitor vital signs , especially BP , closely during initiation of iloprost .Adults .Pulmonary Arterial Hypertension .Oral Inhalation .Administer 6 - 9 times daily at minimum intervals of 2 hours while awake according to clinical response .", "label": "", "metadata": {}, "score": "80.168915"}
{"text": "( A ) Change in pulmonary vascular resistance ( PVR ) index over time on epoprostenol or treprostinil .( B ) Change in mean pulmonary artery pressure ( mPAP ) over time on epoprostenol and treprostinil .", "label": "", "metadata": {}, "score": "80.27052"}
{"text": "Average age at baseline catheterization was 7.7 \u00b1 5.2 years .Sixty - four patients had at least 1 follow - up cardiac catheterization after prostanoid therapy was initiated .", "label": "", "metadata": {}, "score": "80.54405"}
{"text": "[PubMed ] .Rosenzweig EB , Kerstein D , Barst RJ .Long - term prostacyclin for pulmonary hypertension with associated congenital heart defects .", "label": "", "metadata": {}, "score": "80.67273"}
{"text": "Importance of informing clinicians of existing or contemplated concomitant therapy , including prescription and OTC drugs , and dietary and herbal supplements , as well as any concomitant illnesses ( e.g. , liver or kidney disease ) .", "label": "", "metadata": {}, "score": "80.714745"}
{"text": "Importance of informing clinicians of existing or contemplated concomitant therapy , including prescription and OTC drugs , and dietary and herbal supplements , as well as any concomitant illnesses ( e.g. , liver or kidney disease ) .", "label": "", "metadata": {}, "score": "80.714745"}
{"text": "Durongpisitkul K , Jakrapanichakul D , Laohaprasitiporn D , et al .Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease .J Med Assoc Thai 2005 ; 88 : Suppl . 8 S60 -S65 .", "label": "", "metadata": {}, "score": "80.79358"}
{"text": "Satoshi Akagi ( National Hospital Organization Okayama Medical Center , Japan ) and colleagues report their experiences using dobutamine and dopamine for haemodynamic support of 46 patients undergoing epoprostenol therapy for World Health Organization functional class IV PAH .", "label": "", "metadata": {}, "score": "80.804825"}
{"text": "Sub - Q and IV therapy : Headache , diarrhea , nausea , jaw pain , vasodilation , dizziness , edema , pruritus , hypotension .", "label": "", "metadata": {}, "score": "80.92625"}
{"text": "View Article .Mookadam F , Jiamsripong P , Goel R , Warsame TA , Emani UR , Khandheria BK : Critical appraisal on the utility of echocardiography in the management of acute pulmonary embolism .", "label": "", "metadata": {}, "score": "81.025085"}
{"text": "Utsonomiya T : Treatment of pulmonary embolism with prostacyclin .Surgery 1980 , 88 : 25 - 30 .Perlman MB : Effects of prostacyclin on pulmonary vascular response to thrombin in awake sheep .", "label": "", "metadata": {}, "score": "81.23347"}
{"text": "A post - hoc power analysis of our study data indicated that we had 80 % power to detect a difference in RVED between treatment arms as large as 16 % .", "label": "", "metadata": {}, "score": "81.28052"}
{"text": "Moreover , due to small sample sizes and non - normal distributions of biochemical parameters , also a nonparametric test ( Mann - Whitney U ) was performed .", "label": "", "metadata": {}, "score": "81.381775"}
{"text": "Lankeit M , Konstantinides S : Thrombolysis for hemodynamically stable patient with pulmonary embolism : Still searching for the intermediate - risk group .Tromb Res 2009 , in press .", "label": "", "metadata": {}, "score": "81.3918"}
{"text": "Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act ( P.L. 97 414 ) .", "label": "", "metadata": {}, "score": "81.57297"}
{"text": "Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act ( P.L. 97 414 ) .", "label": "", "metadata": {}, "score": "81.57297"}
{"text": "Rate of Administration .IV Administration .For solution compatibility information , see Compatibility under Stability .Must be diluted prior to IV administration .1 14 ( See Dilution under Dosage and Administration . )", "label": "", "metadata": {}, "score": "81.756355"}
{"text": "Of the patients without follow - up hemodynamic data , 6 died , 1 received a heart - lung transplant , 1 is off therapy , and 5 did not receive a follow - up catheterization or complete hemodynamic data were not available for review .", "label": "", "metadata": {}, "score": "81.790825"}
{"text": "[PubMed ] .Barst R. Pharmacokinetics , safety , and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension .Clin Pharmacol Therapeut .", "label": "", "metadata": {}, "score": "82.06116"}
{"text": "He has been a paid lecturer for Actelion , Pfizer , Bayer Schering , and GlaxoSmithKline .His Institute has received grant support from Actelion , Pfizer , United Therapeutics , Eli Lilly , Bayer Schering , Encysive , and GlaxoSmithKline .", "label": "", "metadata": {}, "score": "82.25951"}
{"text": "The mean pulmonary arterial pressure ( mPAP ) , cardiac index ( CI ) , pulmonary vascular resistance , and functional class were significantly improved during the first 6 months of epoprostenol treatment .", "label": "", "metadata": {}, "score": "82.28133"}
{"text": "1 2 Both ampuls deliver a dose of either 2.5 or 5 mcg to the mouthpiece , depending on the drug chamber selected by the clinician . 1 Use the drug chamber with the red latch and the color - matched control disc to deliver a 2.5-mcg dose .", "label": "", "metadata": {}, "score": "82.310745"}
{"text": "1 2 Both ampuls deliver a dose of either 2.5 or 5 mcg to the mouthpiece , depending on the drug chamber selected by the clinician . 1 Use the drug chamber with the red latch and the color - matched control disc to deliver a 2.5-mcg dose .", "label": "", "metadata": {}, "score": "82.310745"}
{"text": "There were 47 patients with IPAH , 24 with repaired CHD - PAH , and 6 with other forms of World Health Organization Group 1 IPAH .", "label": "", "metadata": {}, "score": "82.852066"}
{"text": "Special Populations .In patients with hepatic impairment , elimination is reduced and/or systemic exposure is increased after oral or IV administration .In patients with severe renal impairment , systemic exposure is increased after IV administration in individuals requiring dialysis ; AUC not substantially increased after IV administration in those not requiring dialysis .", "label": "", "metadata": {}, "score": "83.34538"}
{"text": "Special Populations .In patients with hepatic impairment , elimination is reduced and/or systemic exposure is increased after oral or IV administration .In patients with severe renal impairment , systemic exposure is increased after IV administration in individuals requiring dialysis ; AUC not substantially increased after IV administration in those not requiring dialysis .", "label": "", "metadata": {}, "score": "83.34538"}
{"text": "Signed informed consent prior to initiation of any study mandated procedure .Exclusion Criteria : .Patients with respiratory and/or cardiovascular distress in need of emergency care .", "label": "", "metadata": {}, "score": "83.37392"}
{"text": "15 If unable to titrate to target dosage , maintain patient on highest possible tolerated dosage .If a treatment session is missed or interrupted , resume therapy as soon as possible at usual dosage .", "label": "", "metadata": {}, "score": "83.429756"}
{"text": "( % ) or mean ( SD ) .NT - proBNP and troponin T are presented as median ( range ) .Effects on Right Ventricle End - Diastolic Diameter .", "label": "", "metadata": {}, "score": "83.62627"}
{"text": "PubMed .Kucher N , Rossi E , De Rosa M , Goldhaber SZ : Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mmHg or higher .", "label": "", "metadata": {}, "score": "83.80826"}
{"text": "A recent meta - analysis including 23 randomised controlled studies has also shown improvements in survival and a reduction in the hospitalisation rate [ 6 ] .", "label": "", "metadata": {}, "score": "84.09883"}
{"text": "View Article PubMed .Come PC , Kim D , Parker JA , Goldhaber SZ , Breanwald E , Markis JE : Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intraveneous tissue plasminogen activator .", "label": "", "metadata": {}, "score": "84.19661"}
{"text": "Estimation of relevant degrees of RVED or PAP reduction can possibly be derived indirectly from human thrombolysis studies , since thrombolytic treatment was associated with reduced mortality ( 4.7 % vs 11.1 % ) in the setting of right ventricular dilatation in acute pulmonary embolism [ 21 ] .", "label": "", "metadata": {}, "score": "84.25102"}
{"text": "Results .Subjects .The baseline characteristics of the treatment groups were similar , as shown in Table 1 .In both groups treatment was started on average 14 hours after the onset or progression of symptoms .", "label": "", "metadata": {}, "score": "84.464005"}
{"text": "Since pulmonary vasocontriction is an early and partially transient phenomenon in acute pulmonary embolism [ 14 ] , this might explain why animal models show a larger benefit of vasodilator treatment .", "label": "", "metadata": {}, "score": "84.80333"}
{"text": "NT - proBNP concentrations were determined with an immunoradiometric assay kit ( Roche diagnostics , module E170 ; Mannheim , Germany ) .Cardiac troponin T concentrations were determined using a microparticle enzyme immunoassay ( Roche Diagnostics , Module E170 ; Mannheim , Germany ) .", "label": "", "metadata": {}, "score": "85.12218"}
{"text": "The appropriate timing of combination therapy and whether it should be simultaneously or sequential requires further evaluation .A goal - oriented approach to combination therapy seems to be appropriate given the current available data on efficacy and safety .", "label": "", "metadata": {}, "score": "85.89531"}
{"text": "View Article PubMed .Halmagyi DF , Starzecki B , Horner GJ : Humoral transmission of cardiorespiratory changes in experimantal lung embolism .Circ Res 1964 , 14 : 546 - 552 .", "label": "", "metadata": {}, "score": "86.02887"}
{"text": "Any known factor or disease that might interfere with treatment compliance , study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease .", "label": "", "metadata": {}, "score": "86.26148"}
{"text": "The study protocol was approved by the local ethics committee ( METc ) , and written informed consent was obtained from each patient prior to study entry .", "label": "", "metadata": {}, "score": "86.2672"}
{"text": "Importance of informing clinicians of existing or contemplated concomitant therapy , including prescription and OTC drugs , as well as any concomitant illnesses .Importance of informing patients of other important precautionary information . 1 ( See Cautions . )", "label": "", "metadata": {}, "score": "86.3687"}
{"text": "Administer undiluted drug solution by continuous sub - Q infusion via a self - inserted sub - Q catheter , using a controlled - infusion device ( ambulatory infusion pump ) .", "label": "", "metadata": {}, "score": "87.23908"}
{"text": "Created Date : 2013 - 1 - 29 Completed Date : - Revised Date : - .Medline Journal Info : .Nlm Unique ID : 100959226 Medline TA : Mod Rheumatol Country : - .", "label": "", "metadata": {}, "score": "87.33473"}
{"text": "1 Consult manufacturer 's labeling for pump specifications .A peripheral IV catheter ( preferably placed in a large vein ) may be used temporarily until central venous access can be established .", "label": "", "metadata": {}, "score": "87.46678"}
{"text": "Parameters of pulmonary gas exchange ( PaO 2 , PaCO 2 or SaO 2 ) were similar at baseline and did not significantly change during treatment ( data not shown ) .", "label": "", "metadata": {}, "score": "87.48781"}
{"text": "Change in Borg Dyspnea Score From Baseline to EOT .[ Time Frame : Approximately 3 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "87.53851"}
{"text": "The physician providing clinical care and monitoring vital parameters was not blinded in order to be able to respond appropriately if the patient showed signs of hemodynamic or respiratory deterioration .", "label": "", "metadata": {}, "score": "87.5935"}
{"text": "We received editorial assistance from Elements Communications Ltd ( Westerham , UK ) , supported by Actelion Pharmaceuticals Ltd ( Allschwil , Switzerland ) .Hunt SA , Abraham WT , Chin MH , et al .", "label": "", "metadata": {}, "score": "87.83285"}
{"text": "Cerebrovascular events ( e.g. , transient ischemic attack or stroke ) within 6 months of screening .History of myocardial infarction .History of left - sided heart disease , including any of the following : . hemodynamically significant aortic or mitral valve disease . restrictive or congestive cardiomyopathy .", "label": "", "metadata": {}, "score": "87.94934"}
{"text": "The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain .Change in Convenience Score of the Abbreviated Treatment Satisfaction Questionnaire for Medication ( TSQM-9 )", "label": "", "metadata": {}, "score": "87.994415"}
{"text": "Mean Rp / Rs at 9 ... .Eight patients died or received heart - lung transplant within 2 years of baseline catheterization .Mean Rp / Rs , right atrial pressure ( RAP ) , and PVRI were significantly different for this group compared with the rest of the cohort .", "label": "", "metadata": {}, "score": "88.075455"}
{"text": "[ PubMed 15243302 ] .US Food and Drug Administration .Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act ( P.L. 97 - 414 ) .", "label": "", "metadata": {}, "score": "88.13946"}
{"text": "The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain .Change in Global Satisfaction Score of the Abbreviated Treatment Satisfaction Questionnaire for Medication ( TSQM-9 )", "label": "", "metadata": {}, "score": "88.62421"}
{"text": "[PubMed ] .van Loon RL , Roofthooft MT , Delhaas T , et al .Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies .", "label": "", "metadata": {}, "score": "88.6327"}
{"text": "Geriatric Use . 1 Select dosage with caution because of age - related decreases in hepatic , renal , and/or cardiac function and concomitant disease and drug therapy . 1 ( See Geriatric Patients under Dosage and Administration . )", "label": "", "metadata": {}, "score": "88.67059"}
{"text": "Geriatric Use . 1 Select dosage with caution because of age - related decreases in hepatic , renal , and/or cardiac function and concomitant disease and drug therapy . 1 ( See Geriatric Patients under Dosage and Administration . )", "label": "", "metadata": {}, "score": "88.67059"}
{"text": "Other Efficacy End Points .Measurements of systolic PAP , TAPSE , RVFAC , end - diastolic right atrial diameter , end - diastolic right / left ventricular ratio and biochemical parameters of right ventricular overload are presented in Table 2 .", "label": "", "metadata": {}, "score": "88.96235"}
{"text": "Keywords : pediatric patients , pulmonary arterial hypertension , epoprostenol , treprostinil , hemodynamics .Pulmonary arterial hypertension ( PAH ) is characterized by elevation of pulmonary vascular resistance ( PVR ) and pulmonary arterial pressures leading to progressive right heart failure and , ultimately , death .", "label": "", "metadata": {}, "score": "89.75134"}
{"text": "Kaplan - Meier 5-year transplant - free survival was 70 % ( 95 % confidence interval , 56%-80 % ) .CONCLUSION .There was improvement in Rp / Rs on both therapies at 1 to 2 years that was not sustained .", "label": "", "metadata": {}, "score": "89.81112"}
{"text": "Long - term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil .Eur Respir J. 2006 ; 28 : 1195 - 203 .[", "label": "", "metadata": {}, "score": "89.86037"}
{"text": "Pulmonary arterial hypertension in children .Pediatr Pulmonol .[PubMed ] .Mourani PM , Sontag MK , Ivy DD , Abman SH .Effects of long - term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease .", "label": "", "metadata": {}, "score": "89.873955"}
{"text": "Chest 2001 , 120 : 120 - 125 .View Article PubMed .Tardy B , Venet C , Zeni F , Coudrot M , Guyomar'h S , Mismetti P : Short term effect of recombinant tissue plasminogen activator in patients with hemodynamically stable acute pulmonary embolism : Results of a meta - analysis involving 464 patient .", "label": "", "metadata": {}, "score": "89.87913"}
{"text": "Contraindications .Warnings / Precautions .Warnings .Risk of Infection with IV Administration .Risk of serious and potentially fatal blood stream infections ( BSI ) and sepsis associated with drug delivery system ( chronic indwelling central venous catheter ) .", "label": "", "metadata": {}, "score": "90.32479"}
{"text": "View Article PubMed .Alpert JS , Godtfredsen J , Ockene IS , Anas J , Dalen JE : Pulmonary hypertension secondary to minor pulmonary embolism .", "label": "", "metadata": {}, "score": "90.418945"}
{"text": "Panel on Antiretroviral Guidelines for Adults and Adolescents .Guidelines For the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents .Bethesda , Department of Health and Human Services , 2008 ; 1 - 139 .", "label": "", "metadata": {}, "score": "90.44887"}
{"text": "Despite its varying aetiology , all patients with PAH show similar obstructive pathological changes in the small pulmonary arteries and arteriolae , suggesting a common , underlying pathobiology [ 3 ] .", "label": "", "metadata": {}, "score": "90.49225"}
{"text": "D'Alonzo GE , Barst RJ , Ayres SM , et al .Survival in patients with primary pulmonary hypertension .Results from a national prospective registry .", "label": "", "metadata": {}, "score": "90.49887"}
{"text": "These studies demonstrated reductions in right ventricular dimensions ranging from 15 % to 49 % within 24 hours [ 22 - 24 ] .Combining these results , a decrease in RVED of at least 15 % might be the best possible estimation of clinical relevant reduction in RVED .", "label": "", "metadata": {}, "score": "90.60065"}
{"text": "There were similar changes in mean pulmonary artery pressure and pulmonary vascular resistance index .Changes not statistically significant unless noted .Eight patients died or received a transplant within 2 years of baseline ; compared with the rest of the cohort , mean baseline Rp / Rs , right atrial pressure , and pulmonary vascular resistance index were significantly worse in this group .", "label": "", "metadata": {}, "score": "90.78149"}
{"text": "Women of childbearing potential1 must use a reliable method of contraception .Clinical diagnosis of moderate to severe COPD , with an obstructive pattern on pulmonary function tests .", "label": "", "metadata": {}, "score": "90.80597"}
{"text": "The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain .Patients with the following types of pulmonary arterial hypertension ( PAH ) belonging to WHO Group I : Idiopathic ( IPAH ) , Heritable ( HPAH ) , Associated ( APAH ) with Connective tissue diseases or Drugs and toxins .", "label": "", "metadata": {}, "score": "91.17241"}
{"text": "Subjects .A total 82 patients with acute pulmonary embolism , as diagnosed by spiral CT , were screened for eligibility .After informed consent was obtained , patients were screened by transthoracic echocardiography for signs of pulmonary hypertension .", "label": "", "metadata": {}, "score": "91.5403"}
{"text": "Each treatment session generally lasts 4 - 10 minutes .Patients should have immediate access to a back - up system in the event of equipment malfunction .", "label": "", "metadata": {}, "score": "91.659164"}
{"text": "PubMed .Lancet 1993 , 341 : 507 - 511 .View Article PubMed .Metz D , Nazeyrollas P , Mailier B , Jennesseaux C , Tasson S , Maes D , Elaerts J : Regression of right ventricular hypokinesis after thrombolysis in acute pulmonary embolism .", "label": "", "metadata": {}, "score": "91.747314"}
{"text": "From FDA website .Accessed 2005 Aug 10 .Rich S , Rubin LJ , Abenhaim L et al .Executive summary from the World Health Organization world symposium on primary pulmonary hypertension 1998 .", "label": "", "metadata": {}, "score": "92.08713"}
{"text": "From FDA website .Accessed 2005 Aug 10 .Rich S , Rubin LJ , Abenhaim L et al .Executive summary from the World Health Organization world symposium on primary pulmonary hypertension 1998 .", "label": "", "metadata": {}, "score": "92.08713"}
{"text": "PubMed .Lopez - Candales A , Rajagopalan N , Saxena N , Gulyasy B , Edelman K , Bazaz R : Right ventricular systolic function is not the sole determinant of tricuspid annular motion .", "label": "", "metadata": {}, "score": "92.14881"}
{"text": "[PubMed ] .Rubin LJ , Groves BM , Reeves JT , Frosolono M , Handel F , Cato AE .Prostacyclin - induced acute pulmonary vasodilation in primary pulmonary hypertension .", "label": "", "metadata": {}, "score": "92.45532"}
{"text": "PAH .Continuous Sub - Q or IV Infusion .Initially , 1.25 ng / kg per minute .1 If initial dosage is not tolerated , reduce infusion rate to 0.625 ng / kg per minute .", "label": "", "metadata": {}, "score": "92.60989"}
{"text": "The primary end point was the change in RVED between baseline measurement and during treatment ( i.e. measurements 2 and 3 ) .Secondary end points were right ventricular diameter 48 hours after treatment was stopped ( i.e. measurement 4 ) , systolic PAP , tricuspid annular plane systolic excursion ( TAPSE ) , right ventricular fractional area change ( RVFAC ) , serum cardiac troponin T and NT - proBNP .", "label": "", "metadata": {}, "score": "92.76167"}
{"text": "From FDA web site .About .Terms & Privacy .Connect .Subscribe to receive email notifications whenever new articles are published .This material is provided for educational purposes only and is not intended for medical advice , diagnosis or treatment .", "label": "", "metadata": {}, "score": "93.17998"}
{"text": "Standard two - dimensional and Doppler echocardiography was performed with a commercially available Vivid 7 system ( GE medical systems ; Horten , Norway ) using a 3.0 Mhz broadband ( M3S ) transducer ; serial echocardiograms were analysed off - line .", "label": "", "metadata": {}, "score": "93.18481"}
{"text": "Right heart failure .Dyspnea / fatigue may even have been present at rest .Discomfort increased by any PA . .Change in Effectiveness Score of the Abbreviated Treatment Satisfaction Questionnaire for Medication ( TSQM-9 )", "label": "", "metadata": {}, "score": "93.19504"}
{"text": "Advise patients to avoid driving or operating machinery if they experience dizziness or fainting and to consult their clinician about dosage adjustment if fainting persists or worsens .", "label": "", "metadata": {}, "score": "93.90583"}
{"text": "Advise patients to avoid driving or operating machinery if they experience dizziness or fainting and to consult their clinician about dosage adjustment if fainting persists or worsens .", "label": "", "metadata": {}, "score": "93.90583"}
{"text": "The traditional view is that mechanical obstruction by thrombus mass causes pulmonary hypertension .Therefore , treatment focusses on relieving mechanical obstruction , either by anticoagulation if patients are stable , or by thrombolytic therapy in case of hemodynamic instability [ 4 ] .", "label": "", "metadata": {}, "score": "93.913895"}
{"text": "Eur Heart J. 1995 ; 16 : 698 - 703 .[PubMed ] .Melnick L , Barst RJ , Rowan CA , Kerstein D , Rosenzweig EB .", "label": "", "metadata": {}, "score": "94.51103"}
{"text": "12 13 25 Choice of PAH therapy should be individualized ; consider factors such as disease severity , route of administration , potential adverse effects , and patient preference .", "label": "", "metadata": {}, "score": "95.48273"}
{"text": "Am J Cardiol .[PubMed ] Affiliated with .Abstract .Background .Right ventricular dilatation in the setting of acute pulmonary embolism is associated with an adverse prognosis .", "label": "", "metadata": {}, "score": "95.57475"}
{"text": "All analyses were performed using the SPSS statistical software package ( version 15 ; SPSS ; Chicago , IL ) .Data are shown as mean \u00b1 SD or median ( range ) .", "label": "", "metadata": {}, "score": "95.61865"}
{"text": "Pulmonary arterial pressure is not considered a suitable follow - up parameter because it correlates poorly with disease severity and is , therefore , of limited prognostic value [ 12 ] .", "label": "", "metadata": {}, "score": "95.67563"}
{"text": "RVFAC , however , another indicator of right ventricular function , was diminished suggesting at least moderate dysfunction .It is intriguing why TAPSE and RVFAC seem discongruent in our patients .", "label": "", "metadata": {}, "score": "95.685684"}
{"text": "This is supported by the marked discrepancy between hemodynamic manifestations of acute pulmonary embolism and the degree of mechanical obstruction [ 10 ] .Finally , studies in experimental animal models support a crucial role for pulmonary vasoconstriction in acute pulmonary embolism [ 12 , 13 ] .", "label": "", "metadata": {}, "score": "95.74666"}
{"text": "Pulmonary embolism is a frequent and potentially fatal disorder .Despite immediate treatment with anticoagulants , morbidity and mortality are still high when hemodynamically stable patients with pulmonary embolism have echocardiographic signs of acute right ventricular overload [ 1 - 3 ] .", "label": "", "metadata": {}, "score": "96.10684"}
{"text": "Common Adverse Effects .Interactions for Ventavis .Minimally metabolized by CYP isoenzymes . 1 Does not inhibit CYP enzyme system . 1 Pharmacokinetic interaction unlikely with drugs metabolized by CYP isoenzymes .", "label": "", "metadata": {}, "score": "97.3422"}
{"text": "Provenance .Publication of this peer\u2010reviewed article was supported by Actelion Pharmaceuticals Ltd , Switzerland ( unrestricted grant , European Respiratory Review issue 113 ) .", "label": "", "metadata": {}, "score": "97.40225"}
{"text": "Cardiovasc Res 2000 , 48 : 23 - 33 .View Article PubMed .Miller RI , Das S , Anandarangam T , Leibowitz DW , Alderson PO , Thomashow B , Homma S : Association between right ventricular function and perfusion abnormalities in hemodynamically stable patients with acute pulmonary embolism .", "label": "", "metadata": {}, "score": "97.4861"}
{"text": "Class III : marked limitation of PA .Comfortable at rest .Less than ordinary PA : undue dyspnea / fatigue , chest pain , near syncope .", "label": "", "metadata": {}, "score": "98.43414"}
{"text": "Central venous line infection within 90 days prior to screening and/or a history of recurring line infections .Women who are pregnant or breast - feeding .", "label": "", "metadata": {}, "score": "98.728676"}
{"text": "[PubMed ] .Barst RJ , Maislin G , Fishman AP .Vasodilator therapy for primary pulmonary hypertension in children .Circulation .[PubMed ] .", "label": "", "metadata": {}, "score": "99.32556"}
{"text": "[ PMC free article ] [ PubMed ] .Haworth SG , Hislop AA .Treatment and survival in children with pulmonary arterial hypertension : the UK Pulmonary Hypertension Service for Children 2001 - 2006 .", "label": "", "metadata": {}, "score": "99.36731"}
{"text": "Confirmed pulmonary hypertension by right heart catheterization ( RHC ) .Conditions considered as contraindications for cardiopulmonary exercise testing ( CPET ) and/or inability to pedal on a cycle ergometer .", "label": "", "metadata": {}, "score": "99.43268"}
{"text": "The Borg scale is a category - ratio scale , commonly used to evaluate the effects of exercise on dyspnea .Descriptors have been modified by others so that 10 has been labelled \" extremely severe , \" or \" the worst possible dyspnea imaginable .", "label": "", "metadata": {}, "score": "99.457596"}
{"text": "Ordinary PA : no undue dyspnea / fatigue , chest pain , near syncope .Class II : slight limitation of PA .Comfortable at rest .", "label": "", "metadata": {}, "score": "99.83067"}
{"text": "Although treatable , PAH is still an incurable disease .Given the malignant nature of PAH , there is a case for taking an aggressive approach towards treatment .", "label": "", "metadata": {}, "score": "100.42502"}
{"text": "The Student - t test was used to compare RV parameters between treatment arms and to compare relative change of RVED compared to baseline between treatment arms .", "label": "", "metadata": {}, "score": "100.537155"}
{"text": "Yung D , Widlitz AC , Rosenzweig EB , Kerstein D , Maislin G , Barst RJ .Outcomes in children with idiopathic pulmonary arterial hypertension .", "label": "", "metadata": {}, "score": "100.657745"}
{"text": "Chest 2008 , 133 : 358 - 362 .View Article PubMed .Grifoni S , Olivotto I , Cecchini P , Pieralli F , Camaii A , Santoro G , Conti A , Agnelli G , Berni G : Short - term clinical outcome of patients with acute pulmonary embolism , normal blood pressure , and echocardiographic right ventricular dysfunction .", "label": "", "metadata": {}, "score": "101.26797"}
{"text": "Yuichiro Shirai ; Hidekata Yasuoka ; Tsutomu Takeuchi ; Toru Satoh ; Masataka Kuwana .Title : Modern rheumatology / the Japan Rheumatism Association Volume : - ISSN : 1439 - 7609 ISO Abbreviation : Mod Rheumatol Publication Date : 2013 Jan .", "label": "", "metadata": {}, "score": "101.60536"}
{"text": "About .Terms & Privacy .Connect .Subscribe to receive email notifications whenever new articles are published .This material is provided for educational purposes only and is not intended for medical advice , diagnosis or treatment .", "label": "", "metadata": {}, "score": "102.39045"}
{"text": "About .Terms & Privacy .Connect .Subscribe to receive email notifications whenever new articles are published .This material is provided for educational purposes only and is not intended for medical advice , diagnosis or treatment .", "label": "", "metadata": {}, "score": "102.39045"}
{"text": "All patients who were treated for PAH or repaired CHD - PAH at Lucile Packard Children 's Hospital in conjunction with the Vera Moulton Wall Center for Pulmonary Vascular Diseases at Stanford University and Children 's Hospital Colorado were identified through clinical databases .", "label": "", "metadata": {}, "score": "102.4572"}
{"text": "Cardiac output ( left ventricular outflow traject ) was measured with pulse - doppler .The two - dimensional echocardiograms were interpreted by two experienced echocardiographers .", "label": "", "metadata": {}, "score": "103.424706"}
{"text": "Guidelines on diagnosis and treatment of pulmonary arterial hypertension .The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology .", "label": "", "metadata": {}, "score": "103.53763"}
{"text": "To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .For general information , see Learn About Clinical Studies .", "label": "", "metadata": {}, "score": "105.96143"}
{"text": "2002 ; 106 : I76 - 81 .[PubMed ] .Bergstra A , van Dijk RB , Hillege HL , Lie KI , Mook GA .", "label": "", "metadata": {}, "score": "106.15448"}
{"text": "Department of Pulmonology , VU University Medical Center .References .Fr\u00e9mont B , Pacouret G , Jacobi D , Puglisi R , Charbonnier B , de Labriolle A : Prognostic value of echocardiographic right / left ventricular end - diastolic diameter ratio in patients with acute pulmonary embolism .", "label": "", "metadata": {}, "score": "106.99268"}
{"text": "Other factors to take into account include the patient 's physical and mental state , underlying disease and comorbidities , as well as the patient 's priorities and wishes .", "label": "", "metadata": {}, "score": "108.627335"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "109.2225"}
{"text": "Right ventricular function was assessed by TAPSE and RVFAC , right ventricular dimensions by long axis and tricuspid annular size from the apical 4 chamber view .", "label": "", "metadata": {}, "score": "111.601456"}
{"text": "Acknowledgements .The authors would like to thank miss Yolanda de Groot for performing the echocardiographic studies .Competing interests .Anco Boonstra has served as a paid speaker for Actelion ; Yvo M Smulders has no conflicts of interest to disclose .", "label": "", "metadata": {}, "score": "115.670494"}
{"text": "AHFS DI Essentials .\u00a9 Copyright , 2004 - 2016 , Selected Revisions May 1 , 2006 .American Society of Health - System Pharmacists , Inc. , 7272 Wisconsin Avenue , Bethesda , Maryland 20814 .", "label": "", "metadata": {}, "score": "115.857086"}
{"text": "AHFS DI Essentials .\u00a9 Copyright , 2004 - 2016 , Selected Revisions May 1 , 2006 .American Society of Health - System Pharmacists , Inc. , 7272 Wisconsin Avenue , Bethesda , Maryland 20814 .", "label": "", "metadata": {}, "score": "115.857086"}
{"text": "[PubMed ] .Rashid A , Ivy D. Severe paediatric pulmonary hypertension : new management strategies .Arch Dis Child .[ PMC free article ] [ PubMed ] .", "label": "", "metadata": {}, "score": "116.12723"}
{"text": "\" Testing of this protocol is called for at other institutions to validate or further refine the approach presented here .\" Licensed from medwireNews with permission from Springer Healthcare Ltd.", "label": "", "metadata": {}, "score": "118.06438"}
{"text": "Reproduced from [ 7 ] with permission from the publisher .An example of an algorithm for goal - oriented therapy in pulmonary arterial hypertension ( PAH ) .", "label": "", "metadata": {}, "score": "118.47613"}
{"text": "Pulmonary arterial hypertension ( PAH ) is a devastating disease with a traditionally poor prognosis [ 1 ] .The progressive increase in pulmonary vascular resistance ( PVR ) that characterises PAH results in extensive structural changes in the heart , limits exercise capacity and , eventually , leads to right ventricular failure and death [ 2 ] .", "label": "", "metadata": {}, "score": "119.103195"}
{"text": "To view content sources and attributions , please refer to our editorial policy .", "label": "", "metadata": {}, "score": "120.99298"}
{"text": "All rights reserved .Neither of these parties endorse or recommend any commercial products , services , or equipment .News - Medical .Net provides this medical information service in accordance with these terms and conditions .", "label": "", "metadata": {}, "score": "121.09422"}
{"text": "Registration : URL : NCT01014156 .Medical ethical committee : Medisch - ethische toetsingscommissie ( METc ) from the VUmc ( free university medical centre ) .", "label": "", "metadata": {}, "score": "122.124115"}
{"text": "All authors read and approved the final version of the manuscript .Authors ' Affiliations .Department of Internal Medicine , VU University Medical Center .", "label": "", "metadata": {}, "score": "122.33998"}
{"text": "Reproduced from [ 7 ] permission from the publisher .An emerging and fascinating concept relates to the use of first - line combination therapy with two drugs in PAH patients as compared to initial monotherapy .", "label": "", "metadata": {}, "score": "128.4628"}
{"text": "Languages : ENG Pagination : - Citation Subset : - .Affiliation : .Division of Rheumatology , Department of Internal Medicine , Keio University School of Medicine , 35 Shinanomachi , Shinjuku - ku , Tokyo , 160 - 8582 , Japan .", "label": "", "metadata": {}, "score": "133.94388"}
